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1. Introduction 
Alzheimer’s disease (AD), clinically characterized by progressive impairments of memory, 
cognitive functions and behaviors, is a major form of dementia that mainly affects elderly 
individuals. Alzheimer’s Disease International undertook a Delphi study that showed 
worldwide in 2001 there were 24.3 million people with dementia, most of whom with AD; 
and the figure will rise to 42.3 million and 81.1 million in 2020 and 2040, respectively (Ferri 
et al., 2005). It is estimated that dementia causes people over the age of 60 to spend 11.2% of 
their last years living with disability (Morris and Mucke, 2006).The rapid increase in the 
number of dementia patients, most of whom AD patients, imminently calls for effective 
therapeutic prevention and treatment, in particularly, for AD patients (van Marum, 2008). 
The plaque of ǃ-amyloid (Aǃ) and the neurofibrillary tangle composed mainly by hyper-
phosphorylated tau protein are two major pathological hallmarks of AD (Fu et al., 2009). 
Therefore, in developing anti-AD drugs, preventing the generations of abnormal Aǃ and 
hyper-phosphorylated tau proteins is the major target. For example, bapineuzumab, the 
antibody of abnormal Aǃ, semagacestat and tarenflubil, the modulators of Ǆ-secretase, and 
tramiprosate, the blocker of Aǃ aggregation, have been proposed to treat AD by targeting Aǃ 
cascade (Aisen et al., 2007; Ballard et al., 2011; Green et al., 2009; Thakker et al., 2009). 
However, all these drugs have failed in randomized controlled trials (Ballard et al., 2011). 
Although several reasons might be provided to explain why these trials in AD failed, some 
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scientists suggested the Aǃ and tau hypotheses might be invalid (Smith, 2010). They proposed 
that the complexity of AD would require not one single drug, but multiple drugs or a 
multifunctional drug to modify the disease progress (Mangialasche et al., 2010; Smith, 2010). 
The neuropathology of AD is characterized by a decreased cholinergic transmission caused by 
the loss of cholinergic neurons. Acetylcholinesterase (AChE) inhibitors, which enhance the 
function of cholinergic neurons by prolonging the duration in which acetylcholine stays in the 
synaptic clefts, have shown promising potential in the treatment of AD (Li et al., 2007b). The 
inhibitors of AChE could stabilize cognitive and behavior functions of AD patents at a steady 
level for at least 1 year in 50% and up to 2 years in about 24% of treated patients (Wang et al., 
2006). Moreover, those AD patients who do not response to one AChE inhibitor could take 
another (Wang et al., 2006). So far, four AChE inhibitors, namely tacrine (Cognex), donepezil 
(Atricept), rivastigmine (Exelon) and galantamine (Reminyl), have been approved by the U.S. 
Food and Drug Administration (FDA) for the treatment of AD (Ellis, 2005; Francis et al., 2005).  
Huperzine A, a Lycopodium alkaloid discovered from the traditional Chinese medicine 
Huperzia serrata (Qian Ceng Ta) (FIG. 1A), is also widely used in the treatment of AD in 
China (FIG. 1B). It is a selective AChE inhibitor with much higher potency and longer 
duration of AChE inhibition than those of tacrine, donepezil, rivastigmine and galantamine 
(Wang and Tang, 1998; Zhao and Tang, 2002). Double-blind, randomized clinical trials in 
China have demonstrated that huperzine A induces significant improvement in memory in 
elderly people and AD patients without any significant side effects (Wang et al., 2009). 
However, the lack of natural supply of Huperzia serrata and difficulty in its chemical 
synthesis have limited the clinical usage of huperzine A (Zhang and Tang, 2006). 
Memantine (Namenda), which is an uncompetitive antagonist of N-methyl-D-aspartate 
(NMDA) receptors with a fast on-/off-rate, could reduce excessive glutamate-induced 
excitotoxicity. The success of memantine in clinical trials led to its being approved by FDA 
to treat moderate to severe AD in 2003 (Lipton, 2006). This encouraging news pointed to a 
new direction for the development of anti-AD drugs: by boosting the activities of healthy 
neurons and reducing abnormal brain functions (Gravitz, 2011). However, further studies 
have indicated that either AChE inhibitors or NMDA receptor antagonists have limited 
success in reversing AD progress as they are unable to stop neurodegeneration (Roberson 
and Mucke, 2006). 
The effectiveness of multiple drug strategy has been proven. One of the examples is the HIV 
drug cocktail (Zhang, 2005). Combinations of drugs with different targets, are also widely 
used in cancer therapy (Hanahan and Weinberg, 2011). The involvement of multi-factorial 
etiopathogenesis in AD suggests that the treatment of AD may also require multiple drug 
therapy to target its different pathological aspects (Youdim and Buccafusco, 2005). 
However, there are some challenges in the use of drug cocktail strategy that works at 
different therapeutic targets. Different drugs have differences in bioavailability, 
pharmacokinetics and metabolisms. They may also cross-react with one another which in 
turn cause serious side-effects. Therefore, the one-compound-multiple-targets strategy, a 
novel drug development approach pioneered by Prof. Moussa Youdim, has emerged as a 
practical alterative to overcome these challenges (Youdim and Buccafusco, 2005). Designing 
a single molecule synergistically targeting two or more therapeutic pathways is reasonably 
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more proficient than the combination of one-compound-one-target drugs because of simple 
bioavailability and pharmacokinetics. Therefore, many neuroscience research institutes and 
pharmaceutical companies devote the majority of their resources to search for the effective 
one-compound-multi-functional agents for the treatment of AD. 
 
Fig. 1. The chemical structures of huperzine A and bis(12)-hupyridone. 
(A) Chinese medicinal herb Huperzia serrata (Qian Ceng Ta); (B) The structure of huperzine 
A; (C) The structure of bis(12)-hupyridone. 
Our group has devoted enormous efforts in developing drugs that are better efficacy than 
current AChE inhibitors the currently available AChE inhibitors over the past years. With 
the help of scientists from Israel, the USA and China, we have developed a series of novel 
bis(n)-hupyridones by the homo-dimerization of hupyridone, the ineffective fragments of 
huperzine A (Carlier et al., 2000; Wong et al., 2003). These dimeric compounds are easy to 
synthesis and have been shown to be more potent than huperzine A in the inhibition of 
AChE. In this article, we will review that bis(12)-hupyridone (FIG. 1C), one of our novel 
dimeric promising anti-AD candidates, possesses multiple functions that include the 
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enhancement of cognitive functions, the protection against neurotoxins, and the promoting 
of neuronal differentiation for the treatment of AD. 
2. Design and synthesis of novel anti-AChE dimers derived from huperzine A 
By studying the three-dimensional (3D) structure of AChE of Torpedo californica electric 
organ (TcAChE), one active site of AChE, named the “catalytic anionic site”, was found at 
the bottom of a deep narrow gorge (active-site gorge, 20 Å) (Axelsen et al., 1994), The 
quaternary amino group of acetylcholine interacts with the indole side chain of the 
conserved residue Trp84 in a cation-ð interaction at this “catalytic anionic site” (Ma and 
Dougherty, 1997). Moreover, another active site of AChE, named “peripheral anionic site”, 
was also found near the top of the “active-site gorge”, about 14 Å from the “catalytic anionic 
site” (Harel et al., 1993). The major element of the “peripheral anionic site” is the residue of 
Trp279. The bivalent ligand strategy is widely used in the synthesis of novel drugs in which 
identical or different pharmacophores are connected by a suitable linker (Haviv et al., 2005). 
The advantage of this strategy is the chelate effect, which creates a bifunctional ligand with 
enhanced affinity for its target. The molecular structure of AChE with one active site in the 
gorge (“catalytic anionic site”) and another at the extremity (“peripheral anionic site”) 
makes AChE a particularly attractive target to apply this strategy. 
The crystal structure study of the complex of AChE with (-)-huperzine A has shown 
important hydrophobic interactions between (-)-huperzine A and Trp84 at the “catalytic 
anionic site” of AChE (Raves et al., 1997). We initially synthesized hupyridone (5-amino-
2(1H)-quinolinones), a fragment which lacks the C6-C8 bridge of (-)-huperzine A. Although 
this fragment does not show any significant inhibition of AChE, it appears to possess much 
of the intrinsic functionality of (-)-huperzine A (FIG. 1). It retains the pyridine oxygen atom 
and NH group of (-)-huperzine A, which form hydrogen bonds to Tyr-130 and Gly-117, 
respectively (Raves et al., 1997). Most importantly, hupyridone also retains the 5-amino 
group of (-)-huperzine A, which is essential for the inhibitory activity of (-)-huperzine A by 
interacting with Try84. We speculated that it is possible to find high-affinity inhibitors of 
AChE with structure like that of hupyridone. Particularly, the loss of hydrophobic contact in 
the “catalytic anionic site” could be compensated by additional chelating interactions at the 
“peripheral anionic site” (Carlier et al., 2000; Wong et al., 2003). 
A series of hupyridone dimer or bis(n)-hupyridones, with different alkylene chain lengths, has 
been synthesized from 7,8-dihydroquinoline-2,5(1H,6H)-dione by the condensation, the 
reduction and the dimerization (FIG. 2). Computational calculations showed that 12 methylene 
units were the most approximate chain length. The 3D study of TcAChE-ligand complexes has 
shown that bis(12)-hupyridone binds more tightly to TcAChE than (-)-huperzine A (Wong et 
al., 2003). Overlaying the structures of TcAChE with those of bis(12)-hupyridone and (-)-
huperzine A also reveals that the dimer makes cation-ð and hydrogen bonding interactions at 
the “peripheral anionic site” (Trp279), interactions that can contribute to bis(12)-hupyridone’s 
higher affinity compared with (-)-huperzine A (FIG.3) (Wong et al., 2003). It is suggested that 
the tether of the hupyridone unit of bis(12)-hupyridone provides minimal entropy and 
substantially compensates for the weaker and/or missing interactions of (-)-huperzine A with 
AChE (Raves et al., 1997; Wong et al., 2003). 
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Fig. 2. Synthesis of bis(n)-hupyridones. 
 
Fig. 3. Overlay of the refined structures of TcAChE/(-)-bis(10)-hupyridone (sky blue), 
TcAChE/(-)-bis(12)-hupyridone (pink), and TcAChE/(-)huperzine A (yellow). 
Inhibitors and protein residues are rendered as sticks, and water molecules are shown as red 
spheres. The figure is modified from the reference (Wong et al., 2003). 
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3. Multifunctional potencies of bis(12)-hupyridone 
3.1 Inhibition of AChE 
The anti-cholinesterase activities of bis(n)-hupyridones were further tested in vitro and in vivo. 
It has been shown that bis(n)-hupyridones inhibit AChE in a tether-length-dependent manner. 
The 50% inhibitory concentration (IC50) on AChE by bis(12)-hupyridone was about 52 nM, 
which was comparable to those of AChE inhibitors used for treating AD (Table 1) (Li et al., 
2007b). Furthermore, kinetic analysis of bis(12)-hupyridone suggested that the inhibition 
pattern was mixed competitive with an apparent Ki value of 28.9 nM. In vivo study has also 
shown that single p.o. administration of bis(12)-hupyridone significantly inhibit AChE activity 
in various brain regions (cortex, hippocampus, striatum) in rats (Table 2) (Li et al., 2007b). 
 
AChE inhibitors 




(μM) AChE BuChE 
Bis(10)-
hupyridone 0.151 1.82 12.1 N.D. N.D. 
Bis(11)-
hupyridone 0.084 1.16 13.8 N.D. N.D. 
Bis(12)-
hupyridone 
0.052 9.6 185.0 Mixed 28.9 
Bis(13)-
hupyridone 0.052 16.7 321.0 N.D. N.D. 
Bis(14)-
hupyridone 
0.24 59.5 148.0 N.D. N.D. 
Huperzine A 0.082 74.43 907.7 mixed 24.9 
Galantamine 1.995 12.59 6.3 Competitive 210.0 
Donepezil 0.010 5.01 501.0 Noncompetitive 12.5 
Tacrine 0.093 0.074 0.8 Noncompetitive 105 
Table 1. Anti-AChE activities of bis(n)-hupyridones and other AChE inhibitors used in the 
treatment of AD. 
The concentrators of inhibitors yield 50% inhibition of enzyme activity. The cortex 
homogenate was pre-incubated for 5 min with iso-OMPA 0.1 mM. The rate of color 
production was measured spetrophotometrically at 440 nM. N.D.: not determined, Data are 









cortex hippocampus striatum serum 
Bis(12)-
hupyridone 
90 16 ± 5 ** 40 ± 3 ** 28 ± 6 ** NA 
 45 12 ± 3 ** 14 ± 4 ** 12 ± 5 * NA 
 22 11 ± 3 ** 4 ± 3 5 ± 4 NA 
Table 2. Anti-cholinesterase activities of single p.o. administration of bis(12)-hupyridone in 
rats. 
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Values expressed as percentage of inhibition (versus saline control) were the means ± SD. *p 
< 0.05 and **p < 0.01 versus saline group (ANOVA and Dunnett’s test). Basal saline control 
values of cortex, hippocampus and striatum are 1360 ± 70, 1540 ± 150 and 9390 ± 880 A 
values/g protein, respectively. Basal saline control value of serum is 23 ± 5 A values/g 
protein. Data are from the reference (Li et al., 2007b). 
3.2 Blockade of NMDA receptors 
There are increasing evidences that show that the overstimulation of glutamate receptors of 
the NMDA subtype may be involved in the neuronal loss of AD (Lipton, 2006; Parsons et al., 
2007). With the disruption of the neuron-neuron and neuron-glial connections, glutamate 
might be not only improperly cleared, but also inappropriately released. Meanwhile, 
energetically compromised neurons become depolarized because they cannot maintain their 
ionic homeostasis in the absence of energy. The depolarization relieves the normal Mg2+ 
blockade of NMDA receptor-coupled channel, and then excessive stimulation of glutamate 
receptors occurs (Li et al., 2005; Lipton, 2004). Thus the NMDA receptor has been considered 
an attractive therapeutic target for the development of anti-stroke drugs. On the other hand, 
the NMDA receptor, as the major excitatory neurotransmitter receptor in the central nervous 
system, mediates many important physiological processes, such as synaptic plasticity, and 
learning and memory (Petrovic et al., 2005; Villmann and Becker, 2007). The therapeutic 
potential of many powerful NMDA receptor antagonists, such as MK-801, is limited and 
they fail in clinical trials because of the psychotropic side effects resulting from their 
interference with normal brain functions (Parsons et al., 2007). NMDA receptor blockers 
with moderate to low affinity, such as memantine, may inhibit NMDA receptor-mediated 
pathological but not NMDA receptor-mediated physiological functions. This kind of NMDA 
receptor antagonists has been at the center of interest in the search for the next generation of 
neuroprotective drugs for AD (Lipton, 2004; Lipton, 2007). 
Using the receptor-ligand binding assay, bis(12)-hupyridone has been found to compete 
with [3H]MK-801 with a Ki value of 7.7 μM. In the same testing system, memantine and MK-
801 competed with [3H]MK-801with a Ki value of 0.8 and 0.04 μM, respectively (Table 3) (Li 
et al., 2007a) (our unpublished data). These results suggested that bis(12)-hupyridone is a 
moderate NMDA receptor antagonist and thus might be useful in AD therapy. 
 




Table 3. Bis(12)-hupyridones moderator inhibits NMDA receptors at MK-801 site. 
The membrane proteins from rat cerebellar cortex were incubated with 4 nM [3H]MK-
801.and treated with the serial concentrations of bis(12)-hupyridone/memantine/MK-801. 
The Ki values were calculated from the corresponding IC50 values, which were measured 
from the obtained data using at least eight concentrations of each chemical (in duplicates) 
based on the Cheng-Prusoff equation: Ki = IC50/(1+[ligand]/Kd). Data are either from our 
unpublished paper or from the reference (Li et al., 2007a). 
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3.3 Protection against excitotoxicity 
It is well known that the overstimulation of NMDA receptors is essential to the neuronal 
apoptotic cell death induced by glutamate; and that the blockade of NMDA receptors may 
prevent neuronal cell death induced by excitotoxicity (Danysz and Parsons, 2003). We thus 
investigated the neuroprotective effects of bis(12)-hupyridone against excitotoxicity in the 
primary cerebellar granule neurons (CGNs). We have demonstrated that bis(12)-hupyridone 
inhibits glutamate-induced apoptosis in a concentration-dependent manner, and its 
preventive effect is significant even at the low dosage of 1 nM. Further study using 
fluorescein diacetate/propidium iodide double staining, Hoechst 33324 staining and DNA 
fragmentation gel assays have shown that bis(12)-hupyridone significantly reverses the 
glutamate-evoked nuclear condensation, apoptotic bodies and DNA fragmentation, 
indicating that this dimer is a powerful neuroprotectant against excitotoxicity in vitro (FIG. 4 




Fig. 4. Bis(12)-hupyridone prevents neuronal death induced by glutamate in primary CGNs. 
(A) CGNs were pre-incubated with or without 1 µM bis(12)-hupyridone and exposed to 75 
µM glutamate 2 h later. At 24 h after glutamate challenge, CGNs were assayed with a phase 
contrast microscope, fluorescein diacetate/propidium iodide double staining and Hoechst 
33324 staining. Apoptotic nuclei were indicated by white arrows. (B) CGNs were pre-
incubated with bis(12)-hupyridone at different concentrations as indicated and exposed to 
75 µM glutamate 2 h later. Cell viability was measured by MTT assay at 24 h after glutamate 
challenge. (C) The counts of apoptotic bodies by Hoechst staining. (D) Under the same 
treatment conditions as (B), DNA fragmentation was extracted from CGNs after 24 h of 
challenge, and then agarose gel electrophoresis and ethidium bromide staining were used to 
visualize the DNA extracted from the above samples. B12H: bis(12)-hupyridone; Glu: 
glutamate. All data, expressed as percentage of control, were the means ± SEM of three 
separate experiments; *p < 0.05, **p < 0.01 versus glutamate group (ANOVA and Dunnett’s 
test).  
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3.4 Prevention of ROS-induced neuronal toxicity via regulating the VEGFR-2/Akt 
pathway 
Oxidative stress plays an important role in the pathogenesis of AD as it is the main factor in 
the neuronal loss of this disease (Shibata and Kobayashi, 2008; Zhu et al., 2007). Although the 
detailed mechanisms underlying oxidative stress-induced neuronal death remain unknown, 
drugs with antioxidant properties have therapeutic significance in preventing AD (Pratico, 
2008). H2O2 is widely used as a toxicant to establish in vitro models of oxidative stress-induced 
neuronal apoptosis as it is an uncharged and freely diffusible molecule (Lee et al., 2007). 
Using primary CGNs as a cell model, we have demonstrated that bis(12)-hupyridone at a 
low concentration (3 nM) prevents H2O2-induced apoptosis(Cui et al., 2011c). We have also 
shown that this protection of bis(12)-hupyridone is a novel activity that is apart from its 
AChE inhibitory property. The decreased activation of glycogen synthase kinase (GSK) 3ǃ 
was observed after H2O2 exposure, and bis(12)-hupyridone could reverse the altered 
activation of GSK3ǃ, indicating that bis(12)-hupyridone may exert its neuroprotective effects 
via signaling molecule(s) upstream of GSK3ǃ. Our further study using the antibody of 
phosphorylated vascular endothelial growth factor receptor-2 (VEGFR-2) and the inhibitor 
of VEGFR-2 has demonstrated that bis(12)-hupyridone prevents H2O2-induced neuronal 
apoptosis through regulating the VEGFR-2/Akt signaling pathway (FIG. 5) (Cui et al., 
2011c; Liu et al., 2009). We speculated that bis(12)-hupyridone might either directly interact 
with VEGFR-2 as a potential agonist or indirectly facilitate the activation of VEGFR-2 such 
as by stabilizing the dimerization or increasing the endogenous VEGF from elevating its 
translation, transcription or post-transcription (Cui et al., 2011b). Further investigations on 
the exact role that bis(12)-hupyridone plays in the activation of VEGFR-2 are being 
undertaken in our laboratory.  
3.5 Promoting neuronal differentiation via activating α7nAChR 
Currently prescribed drugs that treat AD have shown only modest and symptomatic effects 
by reducing the degree of impairment without preventing or curing the disease. It is 
partially because that these drugs cannot induce neurogenesis to compensate for the 
neurons that have lost their functions (Maggini et al., 2006). Transplantation of stem cells is 
considered a potential strategy as it may provide neurons to replace those that have been 
lost in the brains of AD patients, and reverse the progress of neurodegeneration (Zhongling 
et al., 2009). However, there is one key problem with this strategy as grafted stem cells are 
not able to differentiate into fully mature neurons in the micro-environments of the brain of 
AD patients (Waldau and Shetty, 2008). The application of agents capable of promoting 
neuronal differentiation at the impaired site may be a valid alternative or adjunct to solve 
that problem. 
With the help of rat hippocampus neural stem cells, we have evaluated the effects of bis(12)-
hupyridone in promoting neural stem cell differentiation. The percentage of ǃIII-tubulin 
positively stained neurons gave evidence that the efficacy of 10 μM bis(12)-hupyridone was 
similar to that of 0.5 μM retinoic acid, a potent inducer of neuronal differentiation. 
Moreover, under the same condition, huperzine A was not able to induce differentiation 
(FIG. 6) (Cui et al., 2011a). Bis(12)-hupyridone therefore might be a promising anti-AD drug 
candidate to promote differentiation of neural stem cells. 
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Fig. 5. Bis(12)-hupyridone inhibits H2O2-induced neuronal death from reversing VEGFR-
2/Akt pathway. (A) The preventive functions of bis(12)-hupyridone against H2O2-induced 
cell death could be abolished by specific VEGFR-2 inhibitors in CGNs. CGNs with or 
without 30 min PTK787 (PTK, a specific VEGFR-2 inhibitor) pre-treatment were treated with 
bis(12)-hupyridone at the indicated concentrations for 2 h and then exposed to 30 μM H2O2. 
Cell viability was measured by the MTT assay at 6 h after H2O2 challenge. **p < 0.01 versus 
H2O2 group, and ##p < 0.01versus bis(12)-hupyridone plus H2O2 group (Tukey’s test). (B) 
Bis(12)-hupyridone reversed H2O2-induced decreasing of pTyr1054-VEGFR-2, pSer473-Akt 
and pSer9-GSK3ǃ. CGNs were pre-treated with 3 nM B12H for 2 h and then exposed to 30 
μM H2O2 for 1 h, the total proteins were detected with using the specific antibodies. (C) The 
ratio to optical density (OD) values of pTry1054-VEGFR-2 over ǃ-actin. The figure is 
modified from the reference (Cui et al., 2011c). 
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Fig. 6. Bis(12-hupyridone induces neuronal differentiation in adult rat hippocampus neural 
stem cells. (A) The expression of ǃ-tubulin in neural stem cells was examined by 
fluorescence microscope. Neural stem cells were exposed to 10 μM bis(12)-hupyridone, 5 
μM huperzine A or 1 μM retinoic acid for 48 h. The cells were then subjected to ǃ-tubulin 
immunostaining and 4'-6-diamidino-2-phenylindole (DAPI) staining. (A) Bis(12)-
hupyridone increased the percentage of ǃ-tubulin positive neurons in a concentration-
dependent manner. Neural stem cells were exposed to bis(12)-hupyridone, huperzine A or 
retinoic acid for 48 h, and the percentage of ǃ-tubulin positive neurons was calculated. The 
figure is modified from the reference (Cui et al., 2011a). 
We have also examined the neuronal differentiation promotion effects of bis(12)-hupyridone 
and its underlying mechanisms in the rat PC12 pheochromocytoma cell line, a well studied 
cell model of neuronal differentiation (Vaudry et al., 2002). Bis(12)-hupyridone (3 – 30 μM) 
has been demonstrated to induce neurite outgrowth in a concentration- and time-dependent 
manner with an efficacy that is three times higher than that of huperzine A in PC12 cells 
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(Cui et al., 2011a). Furthermore, mitogen-activated protein kinase kinase (MEK) inhibitor 
and alpha7-nicotinic acetylcholine receptor (ǂ7nAChR) antagonist blocked the neurite 
outgrowth and the activation of extracellular signal-regulated kinase (ERK) induced by 
bis(12)-hupyridone, suggesting that bis(12)-hupyridone potently induces pro-neuronal cells 
into differentiated neurons by activating the ERK pathway via regulating ǂ7nAChR (FIG. 7). 
As ǂ7nAChR is essential for neuronal differentiation in the rat brain, and loss of ǂ7nAChR 
impairs the maturation of dendritic neurons in adult hippocampus (Campbell et al., 2010; Le 
Magueresse et al., 2006), our results provide a novel insight into the possible therapeutic 
potential of bis(12)-hupyridone in treating AD. To date, as other clinically used anti-AD 
drugs such as huperzine A, donepezil and tacrine have also shown some activities in 
inducing neurite outgrowth in different neuronal cell lines in vitro (Table 4), it would be 
quite interesting to compare their effects on promoting neuronal differentiation in certain 
types of neurons, for example, neural stem cells with bis(12)-hupyridone (Cui et al., 2011a; 
De Ferrari et al., 1998; Oda et al., 2007; Sortino et al., 2004; Tang et al., 2005). 
 
Fig. 7. Bis(12)-hupyridone induces neurite outgrowth from activating ǂ7nAChR in PC12 cells. 
(A) The effects of bis(12)-hupyridone in promoting neurite outgrowth were evidenced by the 
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morphological changes and expression of GAP-43. PC12 cells were exposed to 20 μM bis(12)-
hupyridone, 30 μM huperzine A, 3 mM dibutyryl cAMP (dbcAMP) or 100 ng/ml nerve 
growth factor (NGF) for 7 days. The morphological changes of neurites were examined by 
light microscope, and the expressions of GAP-43 were examined by fluorescence microscope. 
Scale bar 5 μm. (B) Induction of neurite outgrowth by bis(12)-hupyridone is in a concentration-
dependent manner. PC12 cells were exposed to bis(12)-hupyridone, huperzine A, dbcAMP or 
NGF for 7 days, and the percentage of cells with neurites was measured. (C) The ǂ7nAChR 
antagonist attenuates the activation of ERK induced by bis(12)-hupyridone. PC12 cells were 
treated with 0.3 μM methyllycaconitine (MLA, a specific α7nAChR antagonist), 10 μM atropine 
(Atr, a specific muscarinic acetylcholine receptor antagonist) or 30 μM PD98059 (PD, a specific 
MEK inhibitor) for 30 min before the administration of 20 μM bis(12)-hupyridone. The total 
proteins were extracted 30 min after the addition of bis(12)-hupyridone for Western blot 
analysis with specific antibodies. (D) The ǂ7nAChR antagonist attenuates the neurite 
outgrowth induced by bis(12)-hupyridone. PC12 cells were incubated with 0.3 μM 
methyllycaconitine, 10 μM atropine or 30 μM PD98059 for 2 h and treated with 20 μM bis(12)-
hupyridone. The percentage of cells with neurites was measured 7 days after treatment with 
bis(12)-hupyridone. The data, expressed as percentage of control, are the mean ± SEM of three 
separate experiments, with **p < 0.01 versus the bis(12)-hupyridone group in employing 




Table 4. Anti-AD drugs promote neuronal differentiation in vitro.  
Data are from references (Cui et al., 2011a; De Ferrari et al., 1998; Oda et al., 2007; Sortino et 
al., 2004; Tang et al., 2005). 
3.6 Enhancement of learning and memory 
It is widely accepted that enhancement of learning and memory is beneficial for AD patients; 
and it has been proven that AChE inhibitors are the most effective agents in promoting 
cognitive functions in AD therapies. Our novel dimer bis(12)-hupyridone has demonstrated 
superior AChE inhibition in vivo. It is reasonable to expect that this dimer could remedy the 
impairments of learning and memory in AD patients. To prove this hypothesis, the model of 
scopolamine-induced performance deficits was used. We have demonstrated that i.p. injection 
of bis(12)-hupyridone (0.088 – 0.352 μmol/kg) significantly shortens the escape latency in 
Morris water maze after scopolamine administration in rats (Li et al., 2007b). Under the same 
condition, the relative potency of bis(12)-hupyridone (0.176 μmol/kg) to reverse the increased 
escape latency was higher than that of huperzine A (0.206 μmol/kg) (FIG. 8) (Li et al., 2007b). 
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Fig. 8. Memory-enhancing effects of huperzine A and bis(12)-hupyridone on scopolamine-
induced performance deficiency. Huperzine A (A) and bis(12)-hupyridone (B) reverse 
scopolamine-induced performance deficiency in rats. Huperzine A (C) and bis(12)-
hupyridone (D) reverse scopolamine-induced decrease in spatial bias (% of total distances 
swum in the training quadrant during spatial probe trial) in rats. All data were expressed as 
means ± SD, *p < 0.05 and **p < 0.01 versus scopolamine group in (C) and (D) (ANOVA and 
Dunnett’s test). The figure is modified from the reference (Li et al., 2007b). 
3.7 Recovery of ischemic insult 
Ischemia-induced insults result from the complex interplay of multiple pathways including 
excitotoxicity, oxidative stress and impairment of neurogenesis (Van der Schyf et al., 2006a). 
And some of these pathways are also underlying the impairments of AD progress. 
Therefore, agents targeting at multiple site for the treatment of stroke may also possess 
therapeutic effects for AD (Weinreb et al., 2009).  
We have demonstrated in the 2-hour middle cerebral artery occlusion (MCAO) rat model, 
that bis(12)-hupyridone (0.70 - 1.41 μmol/kg, i.p.) could improve neurological behavior 
impairment, and reduce infarct volume as well as brain edema after ischemia. In addition, 
TUNEL staining assay has shown that bis(12)-hupyridone at quite a low concentration (0.70 
μmol/kg, i.p.) could prevent cerebral ischemia-induced apoptosis in the penumbra region 
(FIG. 9, our unpublished paper). Compared with the currently used anti-AD drugs,  
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Fig. 9. Bis(12)-hupyridone rescues acute neurological impairments in rats after 2 h of MCAO 
followed by 24 h of reperfusion. Bis(12)-hupyridone was injected i.p. 30 min pre-ischemia 
and 15 min post-ischemia. (A) Representative photos of  2, 3, 5-triphenyltetrazolium 
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chloride (TTC)-stained brain slices showed that the enlarged infarct tissue area 
(pale unstained region) in the ischemic hemisphere of a control rat was reversed in animals 
treated with bis(12)-hupyridone (0.70 μmol/kg) or memantine (92.7 μmol/kg, 15 min post-
ischemia i.p.). Bis(12)-hupyridone at both the concentrations of 0.70 and 1.41 μmol/kg 
reversed the decreases in neurological score (B), total infarction (C) and brain edema (D). (E) 
Bis(12)-hupyridone (0.70 μmol/kg) also rescued the apoptotic neurons in the penumbral 
region. Upper insets show representative photographs of terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL) staining of the cerebral cortex penumbral 
zones of sham-treated rats, control animals, and bis(12)-hupyridone-treated rats. The lower 
panel shows the quantities of the TUNEL-positive cells. The number of TUNEL-positive 
neurons was randomly and double-blindly counted in three representative 
photomicrographs of each slice. B12H: bis(12)-hupyridone; Mem: memantine 92.7 μmol/kg. 
All data were expressed as means ± SEM, *p < 0.05, **p < 0.01 versus control group (ANOVA 
and Dunnett’s test). The figure is adapted from our unpublished paper. 
 
 
Table 5. Anti-AD drugs protect transient ischemia induced impairments. 
N.A.: not applicable. Data are either from our unpublished paper or from references 
(Gorgulu et al., 2000; Iliev et al., 2000; Wang et al., 2008; Xu et al., 2000; Zheng et al., 2008). 
bis(12)-hupyridone has been shown to have high potency in preventing transient ischemia-
induced neuronal impairments (Table 5) (Gorgulu et al., 2000; Iliev et al., 2000; Wang et al., 
2008; Xu et al., 2000; Zheng et al., 2008). This high potency makes this dimer a promising 
drug candidate for the treatment of stroke and AD. 
4. The physicochemical and pharmacokinetic properties of bis(12)-
hupyridone 
To predict the in vivo behaviors of bis(12)-hupyridone after dosing, its physicochemical 
properties have been studied and reported in our previous publication (Yu et al., 2008). As a 
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dihydrochloride salt, bis(12)-hupyridone presents a poor solubility (Sw: 11.16 mg/ml) with 
two ionization constants (pKa1: 7.5 and pKa2: 10.0) in water. Its solubility can be largely 
affected by the ionic strength (mainly the concentration of chloride ion) existed in the 
solution (S: 2.07 mg/ml in saline) and the pH value of the solution (S: 0.75 mg/ml in 
physiological phosphate buffer saline, pH 7.4). In addition, bis(12)-hupyridone has been 
determined to be highly lipophilic due to the symmetric chemical structure. The large 
difference of the oil-water partition coefficients between its neutral form (log PN : 5.4) and 
ionized form (log DpH 7.4 : 1.1) suggests that bis(12)-hupyridone might be able to easily cross 
the biological barriers and reach to the site of effect (i.e. the central nerve system). Further 
investigated by an in vivo study, its maximum inhibition on AChE at mice brain could be 
reached in 15 min after an intraperitoneal injection (i.p., 5.28 μmol/kg) and the effect could 
be lasted for more than 4 h (Yu et al., 2008). 
Previously, bis(12)-hupyridone has been identified to be quite safe both in vitro and in vivo. 
No cytotoxicity was observed in the MTT assay after 3 h incubation of Caco-2 cells with 
bis(12)-hupyridone (264 μM) (Yu et al., 2011)) In addition, no side-effects were observed for 
bis(12)-hupyridone after an intravenous (i.v.) administration to rats even at a dosage as high 
as 8.8 μmol/kg which suggests the good compliance of bis(12)-hupyridone to rats (Yu et al., 
2009). 
The pharmacokinetic properties of bis(12)-hupyridone have been studied and reported (Yu 
et al., 2009). After the i.v. bolus injection (8.8 μmol/kg), bis(12)-hupyridone presents a two-
compartmental elimination in rats with a first-order kinetic process. Comparing to 
huperzine A, bis(12)-hupyridone exhibits a relative faster distribution and elimination (t1/2ǂ: 
1.7 ± 0.4 min and t1/2ǃ: 92.9±7.9 min) in vivo than those of huperzine A (t1/2ǂ: 6.6 ± 1.1min and 
t1/2ǃ: 149±96 min) (Wang et al., 2006). The greater distribution volume and mean blood 
clearance determined (Vd: 7.54 ± 0.88 L/(min kg) and CL: 0.067 ± 0.006 L/(min kg)) suggest 
the extensive tissue distribution and moderate blood elimination of bis(12)-hupyridone in 
rats. Furthermore, the previous pharmacokinetic study has revealed that bis(12)-hupyridone 
could be rapidly absorbed after i.p. administration to rats at a dose of 10 or 20mg/kg (tmax of 
9.33 and 4.75 min, respectively), with an absolute bioavailability of >75% (Yu et al., 2008). It 
suggests that bis(12)-hupyridone could be well absorbed and most of the administrated 
drugs could enter into the systematic circulation after extra-vascular injection. 
Although all the evidence from in vitro and in vivo studies suggest a reasonable permeation 
of bis(12)-hupyridone through the biological barrier after i.p. administration, it is somewhat 
surprising that bis(12)-hupyridone could not detectable in rat blood after oral 
administration (p.o., 50 mg/kg), which suggesting its poor oral bioavailability. In order to 
assess its extent of absorption from the gastrointestinal (GI) tract, the mechanisms of bis(12)-
hupyridone transport in intestine has been evaluated using Caco-2 cell model(Yu et al., 
2011). As reported, bis(12)-hupyridone has been investigated to be a substrate to ATP-
binding cassette (ABC) transporters and its directional transport could be regulated by the 
ABC-transporters mediated efflux. ABC-transporter inhibitors can significantly increase the 
absorptive transport of bis(12)-hupyridone thus facilitating its oral bioavailability. Since 
ABC-transporters are widely presented not only in the intestine but also at the blood-brain 
barrier (Dallas et al., 2006; Murakami and Takano, 2008), combined treatment of bis(12)-
hupyridone with ABC-transporter inhibitors might to be developed as an effective approach 
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to improve its transport through the biological barriers and enhance its pharmacological 
effects at the central nerve system. 
5. Conclusion 
Based on the unique structure of the AChE enzyme and with the help of the bivalent ligand 
strategy, we have developed bis(n)-hupyridone, a novel series of dimers derived from the 
ineffective fragment of huperzine A. These dimers are proven to be potent and selective 
inhibitors of AChE both in vitro and in vivo. Bis(12)-hupyridone is a superior representative 
among these dimers. We have further shown that bis(12)-hupyridone, similar to memantine 
(an FDA approved anti-AD drug), moderately blocks NMDA receptors at the MK-801  
site. Our studies have demonstrated that bis(12)-hupyridone could prevent excitotoxicity-
induced neuronal loss and H2O2-induced neuronal apoptosis. Moreover, this dimer  
could promote neuronal differentiation with an efficacy similar to retinoic acid in neural 
stem cells. In vivo studies have shown that bis(12)-hupyridone possesses excellent efficacy in 
improving learning and memory deficits and protecting against neuronal loss in vivo. Our 
toxicological, physicochemical and pharmacokinetic studies have proved that bis(12)-
hupyridone is promising for in vivo applications. Based on these novel findings, we 
conjecture that bis(12)-hupyridone could benefit AD patients by acting on multiple 
pathological targets concurrently (FIG. 10). As the synergism between anti-AChE, anti-








Fig. 10. Bis(12)-hupyridone acts as a multi-functional dimer for the treatment of AD. 
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therapeutic strategy to prevent and treat neurodegeneration AD, our findings not only 
provide a new direction for the design of effective compounds with multiple targets for the 
prevention and the treatment of AD, but also offer novel insights into the molecular basis 
for the development of potent therapeutic strategies for this disease. 
6. Acknowledgement 
This work was supported by grants from the Research Grants Council of Hong Kong 
(PolyU5609/09M, PolyU5610/11, N_PolyU618/07, AoE/B15/01-II), The Hong Kong 
Polytechnic University (G-U952), the Shenzhen Shuangbai Funding Scheme 2008. We 
sincerely thank Ms. Josephine Leung for editing our manuscript. 
7. References 
Aisen, P.S., Gauthier, S., Vellas, B., Briand, R., Saumier, D., Laurin, J., Garceau, D., (2007). 
Alzhemed: a potential treatment for Alzheimer's disease. Curr Alzheimer Res. Vol. 4, 
No. 4, 473-8. 
Axelsen, P.H., Harel, M., Silman, I., Sussman, J.L., (1994). Structure and dynamics of the 
active site gorge of acetylcholinesterase: synergistic use of molecular dynamics 
simulation and X-ray crystallography. Protein Sci. Vol. 3, No. 2, 188-97. 
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., Jones, E., (2011). Alzheimer's 
disease. Lancet. Vol. 377, No. 9770, 1019-31. 
Campbell, N.R., Fernandes, C.C., Halff, A.W., Berg, D.K., (2010). Endogenous signaling 
through alpha7-containing nicotinic receptors promotes maturation and integration 
of adult-born neurons in the hippocampus. J Neurosci. Vol. 30, No. 26, 8734-44. 
Carlier, P.R., Du, D.M., Han, Y.F., Liu, J., Perola, E., Williams, I.D., Pang, Y.P., (2000). 
Dimerization of an inactive fragment of huperzine A produces a drug with twice 
the potency of the natural product Angew Chem Int Ed Engl. Vol. 39, No. 10, 1775-
1777. 
Cheng, D.H., Ren, H., Tang, X.C., (1996). Huperzine A, a novel promising 
acetylcholinesterase inhibitor. Neuroreport. Vol. 8, No. 1, 97-101. 
Cui, W., Cui, G.Z., Li, W., Zhang, Z., Hu, S., Mak, S., Zhang, H., Carlier, P.R., Choi, C.L., 
Wong, Y.T., Lee, S.M., Han, Y., (2011a). Bis(12)-hupyridone, a novel multifunctional 
dimer, promotes neuronal differentiation more potently than its monomeric natural 
analog huperzine A possibly through alpha7 nAChR. Brain Res. Vol. 1401, No., 10-
7. 
Cui, W., Li, W., Han, R., Mak, S., Zhang, H., Hu, S., Rong, J., Han, Y., (2011b). PI3-K/Akt 
and ERK pathways activated by VEGF play opposite roles in MPP(+)-induced 
neuronal apoptosis. Neurochem Int. Vol., No. 
Cui, W., Li, W., Zhao, Y., Mak, S., Gao, Y., Luo, J., Zhang, H., Liu, Y., Carlier, P.R., Rong, J., 
Han, Y., (2011c). Preventing HO-induced apoptosis in cerebellar granule neurons 
by regulating the VEGFR-2/Akt signaling pathway using a novel dimeric 
antiacetylcholinesterase bis(12)-hupyridone. Brain Res. Vol. 1394, No., 14-23. 
www.intechopen.com
 When Things Go Wrong – Diseases and Disorders of the Human Brain 
 
170 
Dallas, S., Miller, D.S., Bendayan, R., (2006). Multidrug resistance-associated proteins: 
expression and function in the central nervous system. Pharmacol Rev. Vol. 58, No. 
2, 140-61. 
Danysz, W., Parsons, C.G., (2003). The NMDA receptor antagonist memantine as a 
symptomatological and neuroprotective treatment for Alzheimer's disease: 
preclinical evidence. Int J Geriatr Psychiatry. Vol. 18, No. Suppl 1, S23-32. 
De Ferrari, G.V., von Bernhardi, R., Calderon, F.H., Luza, S.C., Inestrosa, N.C., (1998). 
Responses induced by tacrine in neuronal and non-neuronal cell lines. J Neurosci 
Res. Vol. 52, No. 4, 435-44. 
Ellis, J.M., (2005). Cholinesterase inhibitors in the treatment of dementia. J Am Osteopath 
Assoc. Vol. 105, No. 3, 145-58. 
Ferri, C.P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., 
Hasegawa, K., Hendrie, H., Huang, Y., Jorm, A., Mathers, C., Menezes, P.R., 
Rimmer, E., Scazufca, M., (2005). Global prevalence of dementia: a Delphi 
consensus study. Lancet. Vol. 366, No. 9503, 2112-7. 
Francis, P.T., Nordberg, A., Arnold, S.E., (2005). A preclinical view of cholinesterase 
inhibitors in neuroprotection: do they provide more than symptomatic benefits in 
Alzheimer's disease? Trends Pharmacol Sci. Vol. 26, No. 2, 104-11. 
Fu, H., Dou, J., Li, W., Cui, W., Mak, S., Hu, Q., Luo, J., Lam, C.S., Pang, Y., Youdim, M.B., 
Han, Y., (2009). Promising multifunctional anti-Alzheimer's dimer bis(7)-Cognitin 
acting as an activator of protein kinase C regulates activities of alpha-secretase and 
BACE-1 concurrently. Eur J Pharmacol. Vol. 623, No. 1-3, 14-21. 
Gorgulu, A., Kins, T., Cobanoglu, S., Unal, F., Izgi, N.I., Yanik, B., Kucuk, M., (2000). 
Reduction of edema and infarction by Memantine and MK-801 after focal 
cerebral ischaemia and reperfusion in rat. Acta Neurochir (Wien). Vol. 142, No. 11, 
1287-92. 
Gravitz, L., (2011). Drugs: a tangled web of targets. Nature. Vol. 475, No. 7355, S9-11. 
Green, R.C., Schneider, L.S., Amato, D.A., Beelen, A.P., Wilcock, G., Swabb, E.A., Zavitz, 
K.H., (2009). Effect of tarenflurbil on cognitive decline and activities of daily living 
in patients with mild Alzheimer disease: a randomized controlled trial. Jama. Vol. 
302, No. 23, 2557-64. 
Hanahan, D., Weinberg, R.A., (2011). Hallmarks of cancer: the next generation. Cell. Vol. 144, 
No. 5, 646-74. 
Harel, M., Schalk, I., Ehret-Sabatier, L., Bouet, F., Goeldner, M., Hirth, C., Axelsen, P.H., 
Silman, I., Sussman, J.L., (1993). Quaternary ligand binding to aromatic residues in 
the active-site gorge of acetylcholinesterase. Proc Natl Acad Sci U S A. Vol. 90, No. 
19, 9031-5. 
Haviv, H., Wong, D.M., Greenblatt, H.M., Carlier, P.R., Pang, Y.P., Silman, I., Sussman,  
J.L., (2005). Crystal packing mediates enantioselective ligand recognition at  
the peripheral site of acetylcholinesterase. J Am Chem Soc. Vol. 127, No. 31, 11029-
36. 
Iliev, A.I., Traykov, V.B., Mantchev, G.T., Stoykov, I., Prodanov, D., Yakimova, K.S., 
Krushkov, I.M., (2000). A post-ischaemic single administration of galanthamine, a 
www.intechopen.com
Bis(12)-Hupyridone, a Promising Multi-Functional 
Anti-Alzheimer’s Dimer Derived from Chinese Medicine 
 
171 
cholinesterase inhibitor, improves learning ability in rats. J Pharm Pharmacol. Vol. 
52, No. 9, 1151-6. 
Le Magueresse, C., Safiulina, V., Changeux, J.P., Cherubini, E., (2006). Nicotinic modulation 
of network and synaptic transmission in the immature hippocampus investigated 
with genetically modified mice. J Physiol. Vol. 576, No. Pt 2, 533-46. 
Lee, K.Y., Koh, S.H., Noh, M.Y., Park, K.W., Lee, Y.J., Kim, S.H., (2007). Glycogen synthase 
kinase-3beta activity plays very important roles in determining the fate of oxidative 
stress-inflicted neuronal cells. Brain Res. Vol. 1129, No. 1, 89-99. 
Li, W., Pi, R., Chan, H.H., Fu, H., Lee, N.T., Tsang, H.W., Pu, Y., Chang, D.C., Li, C., Luo, J., 
Xiong, K., Li, Z., Xue, H., Carlier, P.R., Pang, Y., Tsim, K.W., Li, M., Han, Y., (2005). 
Novel dimeric acetylcholinesterase inhibitor bis7-tacrine, but not donepezil, 
prevents glutamate-induced neuronal apoptosis by blocking N-methyl-D-aspartate 
receptors. J Biol Chem. Vol. 280, No. 18, 18179-88. 
Li, W., Xue, J., Niu, C., Fu, H., Lam, C.S., Luo, J., Chan, H.H., Xue, H., Kan, K.K., Lee, N.T., 
Li, C., Pang, Y., Li, M., Tsim, K.W., Jiang, H., Chen, K., Li, X., Han, Y., (2007a). 
Synergistic neuroprotection by bis(7)-tacrine via concurrent blockade of N-methyl-
D-aspartate receptors and neuronal nitric-oxide synthase. Mol Pharmacol. Vol. 71, 
No. 5, 1258-67. 
Li, W.M., Kan, K.K., Carlier, P.R., Pang, Y.P., Han, Y.F., (2007b). East meets West in the 
search for Alzheimer's therapeutics - novel dimeric inhibitors from tacrine and 
huperzine A. Curr Alzheimer Res. Vol. 4, No. 4, 386-96. 
Lipton, S.A., (2004). Paradigm shift in NMDA receptor antagonist drug development: 
molecular mechanism of uncompetitive inhibition by memantine in the treatment 
of Alzheimer's disease and other neurologic disorders. J Alzheimers Dis. Vol. 6, No. 
6 Suppl, S61-74. 
Lipton, S.A., (2006). Paradigm shift in neuroprotection by NMDA receptor blockade: 
memantine and beyond. Nat Rev Drug Discov. Vol. 5, No. 2, 160-70. 
Lipton, S.A., (2007). Pathologically activated therapeutics for neuroprotection. Nat Rev 
Neurosci. Vol. 8, No. 10, 803-8. 
Liu, Y., Wen, X.M., Lui, E.L., Friedman, S.L., Cui, W., Ho, N.P., Li, L., Ye, T., Fan, S.T., 
Zhang, H., (2009). Therapeutic targeting of the PDGF and TGF-beta-signaling 
pathways in hepatic stellate cells by PTK787/ZK22258. Lab Invest. Vol. 89, No. 10, 
1152-60. 
Ma, J.C., Dougherty, D.A., (1997). The Cationminus signpi Interaction. Chem Rev. Vol. 97, 
No. 5, 1303-1324. 
Maggini, M., Vanacore, N., Raschetti, R., (2006). Cholinesterase inhibitors: drugs looking for 
a disease? PLoS Med. Vol. 3, No. 4, e140. 
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., Kivipelto, M., (2010). Alzheimer's 
disease: clinical trials and drug development. Lancet Neurol. Vol. 9, No. 7,  
702-16. 
Morris, R., Mucke, L., (2006). Alzheimer's disease: A needle from the haystack. Nature. Vol. 
440, No. 7082, 284-5. 
Murakami, T., Takano, M., (2008). Intestinal efflux transporters and drug absorption. Expert 
Opin Drug Metab Toxicol. Vol. 4, No. 7, 923-39. 
www.intechopen.com
 When Things Go Wrong – Diseases and Disorders of the Human Brain 
 
172 
Oda, T., Kume, T., Katsuki, H., Niidome, T., Sugimoto, H., Akaike, A., (2007). Donepezil 
potentiates nerve growth factor-induced neurite outgrowth in PC12 cells. J 
Pharmacol Sci. Vol. 104, No. 4, 349-54. 
Parsons, C.G., Stoffler, A., Danysz, W., (2007). Memantine: a NMDA receptor antagonist that 
improves memory by restoration of homeostasis in the glutamatergic system--too 
little activation is bad, too much is even worse. Neuropharmacology. Vol. 53, No. 6, 
699-723. 
Petrovic, M., Horak, M., Sedlacek, M., Vyklicky, L., Jr., (2005). Physiology and pathology of 
NMDA receptors. Prague Med Rep. Vol. 106, No. 2, 113-36. 
Pratico, D., (2008). Evidence of oxidative stress in Alzheimer's disease brain and antioxidant 
therapy: lights and shadows. Ann N Y Acad Sci. Vol. 1147, No., 70-8. 
Raves, M.L., Harel, M., Pang, Y.P., Silman, I., Kozikowski, A.P., Sussman, J.L., (1997). 
Structure of acetylcholinesterase complexed with the nootropic alkaloid, (-)-
huperzine A. Nat Struct Biol. Vol. 4, No. 1, 57-63. 
Roberson, E.D., Mucke, L., (2006). 100 years and counting: prospects for defeating 
Alzheimer's disease. Science. Vol. 314, No. 5800, 781-4. 
Shibata, N., Kobayashi, M., (2008). The role for oxidative stress in neurodegenerative 
diseases. Brain Nerve. Vol. 60, No. 2, 157-70. 
Smith, A.D., (2010). Why are drug trials in Alzheimer's disease failing? Lancet. Vol. 376, No. 
9751, 1466. 
Sortino, M.A., Frasca, G., Chisari, M., Platania, P., Chiechio, S., Vancheri, C., Copani, A., 
Canonico, P.L., (2004). Novel neuronal targets for the acetylcholinesterase inhibitor 
donepezil. Neuropharmacology. Vol. 47, No. 8, 1198-204. 
Tang, L.L., Wang, R., Tang, X.C., (2005). Effects of huperzine A on secretion of nerve growth 
factor in cultured rat cortical astrocytes and neurite outgrowth in rat PC12 cells. 
Acta Pharmacol Sin. Vol. 26, No. 6, 673-8. 
Thakker, D.R., Weatherspoon, M.R., Harrison, J., Keene, T.E., Lane, D.S., Kaemmerer, W.F., 
Stewart, G.R., Shafer, L.L., (2009). Intracerebroventricular amyloid-beta antibodies 
reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged 
Tg2576 mice. Proc Natl Acad Sci U S A. Vol. 106, No. 11, 4501-6. 
van Marum, R.J., (2008). Current and future therapy in Alzheimer's disease. Fundam Clin 
Pharmacol. Vol. 22, No. 3, 265-74. 
Vaudry, D., Stork, P.J., Lazarovici, P., Eiden, L.E., (2002). Signaling pathways for PC12  
cell differentiation: making the right connections. Science. Vol. 296, No. 5573, 1648-
9. 
Villmann, C., Becker, C.M., (2007). On the hypes and falls in neuroprotection: targeting the 
NMDA receptor. Neuroscientist. Vol. 13, No. 6, 594-615. 
Waldau, B., Shetty, A.K., (2008). Behavior of neural stem cells in the Alzheimer brain. Cell 
Mol Life Sci. Vol. 65, No. 15, 2372-84. 
Wang, J., Zhang, H.Y., Tang, X.C., (2009). Cholinergic deficiency involved in vascular 
dementia: possible mechanism and strategy of treatment. Acta Pharmacol Sin. Vol. 
30, No. 7, 879-88. 
www.intechopen.com
Bis(12)-Hupyridone, a Promising Multi-Functional 
Anti-Alzheimer’s Dimer Derived from Chinese Medicine 
 
173 
Wang, R., Yan, H., Tang, X.C., (2006). Progress in studies of huperzine A, a natural 
cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin. Vol. 27, 
No. 1, 1-26. 
Wang, T., Tang, X.C., (1998). Reversal of scopolamine-induced deficits in radial maze 
performance by (-)-huperzine A: comparison with E2020 and tacrine. Eur J 
Pharmacol. Vol. 349, No. 2-3, 137-42. 
Wang, Z.F., Wang, J., Zhang, H.Y., Tang, X.C., (2008). Huperzine A exhibits anti-
inflammatory and neuroprotective effects in a rat model of transient focal cerebral 
ischemia. J Neurochem. Vol. 106, No. 4, 1594-603. 
Wong, D.M., Greenblatt, H.M., Dvir, H., Carlier, P.R., Han, Y.F., Pang, Y.P., Silman, I., 
Sussman, J.L., (2003). Acetylcholinesterase complexed with bivalent ligands related 
to huperzine a: experimental evidence for species-dependent protein-ligand 
complementarity. J Am Chem Soc. Vol. 125, No. 2, 363-73. 
Xu, J., Murakami, Y., Matsumoto, K., Tohda, M., Watanabe, H., Zhang, S., Yu, Q., Shen, J., 
(2000). Protective effect of Oren-gedoku-to (Huang-Lian-Jie-Du-Tang) against 
impairment of learning and memory induced by transient cerebral ischemia in 
mice. J Ethnopharmacol. Vol. 73, No. 3, 405-13. 
Youdim, M.B., Buccafusco, J.J., (2005). CNS Targets for multi-functional drugs in the 
treatment of Alzheimer's and Parkinson's diseases. J Neural Transm. Vol. 112, No. 4, 
519-37. 
Yu, H., Li, W.M., Kan, K.K., Ho, J.M., Carlier, P.R., Pang, Y.P., Gu, Z.M., Zhong, Z., Chan, K., 
Wang, Y.T., Han, Y.F., (2008). The physicochemical properties and the in vivo 
AChE inhibition of two potential anti-Alzheimer agents, bis(12)-hupyridone and 
bis(7)-tacrine. J Pharm Biomed Anal. Vol. 46, No. 1, 75-81. 
Yu, H., Li, W.M., Cheung, M.C., Zuo, Z., Carlier, P.R., Gu, Z.M., Chan, K., Huang, M., Wang, 
Y.T., Han, Y.F., (2009). Development and validation of an HPLC-DAD method for 
bis(12)-hupyridone and its application to a pharmacokinetic study. J Pharm Biomed 
Anal. Vol. 49, No. 2, 410-4. 
Yu, H., Hu, Y.Q., Ip, F.C., Zuo, Z., Han, Y.F., Ip, N.Y., (2011). Intestinal transport of bis(12)-
hupyridone in Caco-2 cells and its improved permeability by the surfactant Brij-35. 
Biopharm Drug Dispos. Vol. 32, No. 3, 140-50. 
Zhang, H.Y., (2005). One-compound-multiple-targets strategy to combat Alzheimer's 
disease. FEBS Lett. Vol. 579, No. 24, 5260-4. 
Zhang, H.Y., Tang, X.C., (2006). Neuroprotective effects of huperzine A: new therapeutic 
targets for neurodegenerative disease. Trends Pharmacol Sci. Vol. 27, No. 12,  
619-25. 
Zhao, Q., Tang, X.C., (2002). Effects of huperzine A on acetylcholinesterase isoforms in vitro: 
comparison with tacrine, donepezil, rivastigmine and physostigmine. Eur J 
Pharmacol. Vol. 455, No. 2-3, 101-7. 
Zheng, C.Y., Zhang, H.Y., Tang, X.C., (2008). Huperzine A attenuates mitochondrial 
dysfunction after middle cerebral artery occlusion in rats. J Neurosci Res. Vol. 86, 
No. 11, 2432-40. 
Zhongling, F., Gang, Z., Lei, Y., (2009). Neural stem cells and Alzheimer's disease: 
challenges and hope. Am J Alzheimers Dis Other Demen. Vol. 24, No. 1, 52-7. 
www.intechopen.com
 When Things Go Wrong – Diseases and Disorders of the Human Brain 
 
174 
Zhu, X., Su, B., Wang, X., Smith, M.A., Perry, G., (2007). Causes of oxidative stress in 
Alzheimer disease. Cell Mol Life Sci. Vol. 64, No. 17, 2202-10. 
www.intechopen.com
When Things Go Wrong - Diseases and Disorders of the Human
Brain
Edited by Dr. Theo Mantamadiotis
ISBN 978-953-51-0111-6
Hard cover, 238 pages
Publisher InTech
Published online 29, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri Slavka Krautzeka 83/A 51000 Rijeka, Croatia Phone: +385 (51) 770 447 Fax: +385 (51) 686 166www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 Fax: +86-21-62489821
In this book we have experts writing on various neuroscience topics ranging from mental illness, syndromes,compulsive disorders, brain cancer and advances in therapies and imaging techniques. Although diverse, thetopics provide an overview of an array of diseases and their underlying causes, as well as advances in thetreatment of these ailments. This book includes three chapters dedicated to neurodegenerative diseases,undoubtedly a group of diseases of huge socio-economic importance due to the number of people currentlysuffering from this type of disease but also the prediction of a huge increase in the number of peoplebecoming afflicted. The book also includes a chapter on the molecular and cellular aspects of brain cancer, adisease which is still amongst the least treatable of cancers.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Wei Cui, Tony Chung-Lit Choi, Shinghung Mak, Hua Yu, Shengquan Hu, Wenming Li, Zhong Zuo and YifanHan (2012). Bis(12)-Hupyridone, a Promising Multi-Functional Anti-Alzheimer’s Dimer Derived from ChineseMedicine, When Things Go Wrong - Diseases and Disorders of the Human Brain, Dr. Theo Mantamadiotis(Ed.), ISBN: 978-953-51-0111-6, InTech, Available from: http://www.intechopen.com/books/when-things-go-wrong-diseases-and-disorders-of-the-human-brain/bis-12-hupyridone-a-promising-multi-functional-anti-alzheimer-s-dimer-derived-from-chinese-medicine
